ANVS_OUT_1 [2025-04-24 05:08:11 -0400] 5283 Bytes | 1465 tokens | Cum: 1465 tkns (18.31% of 8k)
==========================================================================

Listen up, partner—it's 5:08 AM on Thu Apr 24, 2025, and I’m revved up about Annovis Bio (ANVS), climbing from $1.47 to $1.63. This stock is buzzing big-time—do we have a hidden gem, or a flash in the pan? Help me sift through the data!

--- COMPANY PROFILE ---
Company: Annovis Bio (ANVS)
IPO: 2020-01-29 (5 Years Ago)
Market Cap: $24,552,651
Shares Outstanding: 19,490,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNYS
Description: Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.

Here’s a list of headlines for Annovis Bio:

Mar-27-25 04:30PM - Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE
Mar-25-25 08:00AM - Annovis to Attend AD/PD 2025 with Extensive Scientific Program
Mar-21-25 05:05PM - Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results
Mar-11-25 08:00AM - Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment
Feb-19-25 08:30AM - Annovis to Host Patients' Live Forum on February 27, 2025
Feb-07-25 08:00AM - Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference
Feb-06-25 11:21AM - Annovis begins treatment of subjects in Alzheimers trial
Feb-06-25 11:21AM 08:20AM - Annovis Bio announces first patients entered Phase 3 study of buntanetap
Feb-05-25 08:00AM - Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer's Disease
Feb-04-25 04:31PM - Annovis Bio, Inc. Announces Closing of $21 Million Public Offering
Feb-03-25 06:22AM - Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering
Jan-31-25 08:14PM - Annovis Bio, Inc. Announces Proposed Public Offering
Jan-15-25 08:11AM - Annovis Bio granted U.S. patent covering buntanetap
Jan-14-25 08:00AM - Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection
Jan-07-25 08:00AM - FDA Accepts Final Protocol for Pivotal Phase 3 Alzheimer's Disease Study, Streamlining Development Pathway
Dec-05-24 08:30AM - Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today's Marketplace
Dec-04-24 02:21PM - Annovis CEO Discusses Breakthrough Drug for Neurodegenerative Diseases on Today's Marketplace
Nov-25-24 08:00AM - Annovis to Host Year-End Investor Webcast on December 11, 2024
Nov-12-24 08:00AM - Annovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB)
Nov-11-24 08:00AM - Annovis Bio Reports Third Quarter Financial Results and Provides Business Update
Nov-07-24 08:00AM - Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist
Oct-31-24 08:00AM - IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-03-25T12:00:00Z - Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program
B2 - 2025-03-03T18:00:00Z - LEQEMBI Market Sales Reflect Growing Confidence in Disease-Modifying Alzheimer’s Treatments| DelveInsight
B3 - 2025-02-13T18:00:00Z - Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel and Extensive 22+ Therapies Likely to Enter in the Domain | DelveInsight
B4 - 2025-02-07T13:00:00Z - Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference
B5 - 2025-02-05T13:00:00Z - Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease
B6 - 2025-02-01T01:14:00Z - Annovis Bio, Inc. Announces Proposed Public Offering

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Annovis Bio (ANVS).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

ANVS_OUT_3 [2025-04-24 05:08:12 -0400] 910 Bytes | 249 tokens | Cum: 1716 tkns (21.45% of 8k)
==========================================================================

Showing B5 (chunk 1 of 1): B5:
**Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/02/05/3021101/0/en/Annovis-Announces-First-Patients-Entered-into-Pivotal-Phase-3-Study-of-Buntanetap-for-Early-Alzheimer-s-Disease.htmlAnnovis Bio Inc. has announced the start of a pivotal Phase 3 study evaluating its drug candidate buntanetap for the treatment of early Alzheimer's disease. The study aims to assess the safety and efficacy of buntanetap in improving cognition and functional ability in patients.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ANVS_OUT_5 [2025-04-24 05:08:13 -0400] 976 Bytes | 299 tokens | Cum: 2017 tkns (25.21% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-21T21:05:49Z - 12 Health Care Stocks Moving In Monday's After-Market Session - Annovis Bio (NYSE:ANVS), Adial Pharm...
A2 - 2025-04-21T17:05:41Z - 12 Health Care Stocks Moving In Monday's Intraday Session - Annovis Bio (NYSE:ANVS), Adagio Medical ...
A3 - 2025-03-31T17:14:05Z - Annovis Bio stock hits 52-week low at $1.52 amid sharp decline By Investing.com...
A4 - 2025-03-31T17:14:06Z - Annovis Bio stock hits 52-week low at $1.52 amid sharp decline By Investing.com...
A5 - 2025-03-31T17:14:05Z - Annovis Bio stock hits 52-week low at $1.52 amid sharp decline By Investing.com...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

ANVS_OUT_7 [2025-04-24 05:08:14 -0400] 1181 Bytes | 354 tokens | Cum: 2373 tkns (29.66% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**12 Health Care Stocks Moving In Monday's After-Market Session - Annovis Bio (NYSE:ANVS), Adial Pharmaceuticals (NASDAQ:ADIL)**Date: 2025-04-21Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/04/44912134/12-health-care-stocks-moving-in-mondays-after-market-sessionGainers China SXT Pharmaceuticals SXTC shares increased by 23.5% to $1.26 during Monday's after-market session. The company's market cap stands at $17.3 million. Beyond Air XAIR stock increased by 21.05% to $0.28. The company's market cap stands at $24.7 million. Annovis Bio ANVS shares moved upwards by 8.08% to $1.46. The company's market cap stands at $28.4 million. Protagenic Therapeutics PTIX shares rose 7.65% to $0.23. The company's market cap stands at $1.6 million. Adial Pharmaceuticals ADIL shares increased by 7.63% to $0.72. The market value of

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ANVS_OUT_9 [2025-04-24 05:08:15 -0400] 1181 Bytes | 346 tokens | Cum: 2721 tkns (34.01% of 8k)
==========================================================================

Showing A1 (chunk 2 of 3): their outstanding shares is at $4.7 million. cbdMD YCBD shares rose 7.03% to $0.24. The company's market cap stands at $1.5 million. Losers Universe Pharmaceuticals UPC shares declined by 15.7% to $3.49 during Monday's after-market session. The company's market cap stands at $53.1 million. ZyVersa Therapeutics ZVSA shares decreased by 11.42% to $0.62. The company's market cap stands at $1.5 million. Medpace Hldgs MEDP stock decreased by 10.04% to $260.0. The market value of their outstanding shares is at $7.9 billion. The company's, Q1 earnings came out today. Precipio PRPO shares fell 9.19% to $5.24. The market value of their outstanding shares is at $7.7 million. Enveric Biosciences ENVB shares declined by 7.57% to $1.1. The company's market cap stands at $2.7 million. Calidi Biotherapeutics CLDI shares declined by 6.8% to $0.41. The market value of their outstanding shares is at $13.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ANVS_OUT_11 [2025-04-24 05:08:16 -0400] 1120 Bytes | 368 tokens | Cum: 3091 tkns (38.64% of 8k)
==========================================================================

Showing A1 (chunk 3 of 3): 0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADILAdial Pharmaceuticals Inc$0.6500-5.25%Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock - anytime.

Reveal Full ScoreEdge RankingsMomentum10.37Price TrendShortMediumLongOverviewANVSAnnovis Bio Inc$1.4619.6%CLDICalidi Biotherapeutics Inc$0.4101-11.4%ENVBEnveric Biosciences Inc$1.10-5.98%MEDPMedpace Holdings Inc$260.00-12.3%PRPOPrecipio Inc$5.24-11.6%PTIXProtagenic Therapeutics Inc$0.2250-6.21%SXTCChina SXT Pharmaceuticals Inc$1.23-43.1%UPCUniverse Pharmaceuticals Inc$3.49-1.97%XAIRBeyond Air Inc$0.280016.9%YCBDcbdMD Inc$0.24506.52%ZVSAZyVersa Therapeutics Inc$0.6201-11.3%Market News and Data brought to you by Benzinga APIs

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ANVS_OUT_13 [2025-04-24 05:08:18 -0400] 1115 Bytes | 278 tokens | Cum: 3371 tkns (42.14% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-27 8-K Item 7.01 Regulation FD Disclosure

The Company issued a press release announcing the receipt of the Notice. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference.

The information in this report (inclu...

S2 - 2025-03-21 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper.

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes appearing at the...

S3 - 2025-02-04 8-K Item 1.01 Entry into a Material Definitive Agrmt.

On February 3, 2025, Annovis Bio, Inc. (the Company ) entered into an Underwriting Agrmt (the Underwriting Agrmt ) with ThinkEquity LLC, acting as representative of the underwriters ( ThinkEquity ) with respect to an...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ANVS_OUT_15 [2025-04-24 05:08:19 -0400] 1181 Bytes | 271 tokens | Cum: 3644 tkns (45.55% of 8k)
==========================================================================

Showing S1 (chunk 1 of 4): S1:
Item 7.01 Regulation FD Disclosure

The Company issued a press release announcing the receipt of the Notice. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference.

The information in this report (including Exhibit 99.1) shall not be deemed to be filed for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Cautionary Note Regarding Forward-Looking Statements

This report and the furnished press release contains, and oral statements made from time to time by our represe

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ANVS_OUT_17 [2025-04-24 05:08:19 -0400] 1181 Bytes | 236 tokens | Cum: 3882 tkns (48.52% of 8k)
==========================================================================

Showing S1 (chunk 2 of 4): ntatives may contain, forward-looking statements. Forward-looking statements include statements identified by words such as could, may, might, will, intends, plans, seeks, believes, estimates, expects, continues, projects and similar references to future periods, or by the inclusion of forecasts or projections. Forward-looking statements are based on our current expectations and assumptions regarding capital market conditions, our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, our actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements i

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ANVS_OUT_19 [2025-04-24 05:08:20 -0400] 1181 Bytes | 255 tokens | Cum: 4139 tkns (51.74% of 8k)
==========================================================================

Showing S1 (chunk 3 of 4): nclude, but are not limited to, the Companys ability to develop a plan to regain compliance with the continued listing criteria of the NYSE; the NYSEs acceptance of such plan; the Companys ability to execute such plan and to continue to comply with applicable listing standards within the available cure period; risks arising from the potential suspension of trading of the Companys common stock on the NYSE; regional, national or global political, economic, business, competitive, market and regulatory conditions, including risks regarding our ability to manage inventory or anticipate consumer demand; changes in consumer confidence and spending; our competitive environment; our failure to open new profitable stores or successfully enter new markets and other factors set forth under Risk Factors in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024. Any forward-looking

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ANVS_OUT_21 [2025-04-24 05:08:21 -0400] 535 Bytes | 131 tokens | Cum: 4272 tkns (53.40% of 8k)
==========================================================================

Showing S1 (chunk 4 of 4): statement made in this report speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise....

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ANVS_OUT_23 [2025-04-24 05:08:27 -0400] 5877 Bytes | 1564 tokens | Cum: 5840 tkns (73.00% of 8k)
==========================================================================

This is our set of metrics for Annovis Bio.
Please analyze the numbers.

+---------------------+-----------------------+-------------------------+-----------------------+
| Volume: 539,544 | Perf Month: -18.38% | Option/Short: Yes / Yes | Sales Y/Y TTM: - |
+---------------------+-----------------------+-------------------------+-----------------------+
| Avg Volume: 490.72K | Perf Quarter: -71.56% | Short Float: 12.11% | ROE: -3159.09% |
+---------------------+-----------------------+-------------------------+-----------------------+
| Rel Volume: 1.11 | Index: - | Short Ratio: 4.12 | ROI: -264.20% |
+---------------------+-----------------------+-------------------------+-----------------------+
| RSI (14): 48.41 | Market Cap: 29.42M | Short Interest: 2.02M | Sales Surprise: - |
+---------------------+-----------------------+-------------------------+-----------------------+
| ATR (14): 0.18 | Shs Outstand: 19.49M | Beta: 1.43 | EPS Surprise: -58.09% |
+---------------------+-----------------------+-------------------------+-----------------------+
| SMA20: 6.90% | Shs Float: 16.67M | Sales Q/Q: - | P/E: - |
+---------------------+-----------------------+-------------------------+-----------------------+
| SMA50: -12.80% | Inst Own: 13.22% | Sales past 5Y: 0.00% | Earnings: Mar 21 AMC |
+---------------------+-----------------------+-------------------------+-----------------------+
| SMA200: -75.53% | Insider Own: 14.45% | Employees: 8 | |
+---------------------+-----------------------+-------------------------+-----------------------+
| Perf Week: 23.77% | Insider Trans: 0.00% | Debt/Eq: 0.00 | |
+---------------------+-----------------------+-------------------------+-----------------------+

The next section covers any insider trading by Annovis Bio officers or majority shareholders (if available).

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -24590375.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.51
Average Volume: 440539.29
30-Day High: 1.97
30-Day Low: 1.22

[Detailed Financials: TTM 2024]
- Total Assets: $13,925,633.00
- Total Liabilities: $4,617,987.00
- Total Equity: $9,307,646.00
- Current Assets: $13,925,633.00
- Current Liabilities: $3,880,987.00

[Income Statement: TTM 2024]
- Revenue: $0.00
- Net Income: $-24,590,375.00
- Gross Profit: N/A
- Operating Income: $-26,694,928.00
- Earnings Per Share (EPS): -2.02

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $0.00

[Detailed Financials: FY 2024]
- Total Assets: $13,925,633.00
- Total Liabilities: $4,617,987.00
- Total Equity: $9,307,646.00
- Current Assets: $13,925,633.00
- Current Liabilities: $3,880,987.00

[Income Statement: FY 2024]
- Revenue: $0.00
- Net Income: $-24,590,375.00
- Gross Profit: N/A
- Operating Income: $-26,694,928.00
- Earnings Per Share (EPS): -2.02

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $0.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Annovis Bio (ANVS).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Annovis Bio.

2) MARKET_SCORE[]
This conversation was initiated because ANVS is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for ANVS.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, ANVS could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect ANVS to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Annovis Bio.

11) ETHICAL_RATING[]
Rate Annovis Bio’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Annovis Bio.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

ANVS_IN_25 [2025-04-24 05:08:28 -0400] 126 Bytes | 29 tokens | Cum: 6085 tkns (76.06% of 8k)
==========================================================================

====================================
[2025-04-24 05:08:28] # Analysis Completed
Elapsed Time: 17.65 seconds